Bristol-Myers, Novartis bid for DuPont's drug business

Article Abstract:

Novartis AG and Bristol-Myers Squibb Co. have made offers to acquire DuPont Co.'s pharmaceuticals operations. The sale of the operations is expected raise over $6 billion (7.08 billion euros).

Author: Warren, Susan, Raghavan, Anita, Harris, Gardiner
Publisher: Dow Jones Publishing Co. (Europe)
Publication Name: Wall Street Journal. Europe
Subject: Business, international
ISSN: 0921-9986
Year: 2001
Foreign operations, E.I. du Pont de Nemours and Co., Bristol-Myers Squibb Co., BMY

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA

Merck acquires drug researcher in equity deal

Article Abstract:

Merck and Co. said that it has acquired Rosetta Inpharmatics Inc. of Kirkland, Washington. The deal is valued at approximately $620 million (707.3 million euros).

Author: Harris, Gardiner, Regalado, Antonio
Publisher: Dow Jones Publishing Co. (Europe)
Publication Name: Wall Street Journal. Europe
Subject: Business, international
ISSN: 0921-9986
Year: 2001
Prepackaged software, Software Publishers, Engineering, Mfg Software Pkgs (Micro), Computer software industry, Software industry, Scientific software, Engineering software, Merck & Company Inc., Rosetta Inpharmatics Inc.

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA

Novartis explores options on Aventis; giant Swiss drug maker weighs white knight role aimed at thwarting Sanofi

Article Abstract:

Swiss pharmaceutical giant Novartis AG is considering acquiring Aventis SA. This potential friendly merger would thwart the 46 billion Euro hostile takeover of Aventis launched by Sanofi-Synthelabo, SA in late Jan 2004.

Author: Naik, Gautam, Raghavan, Anita
Publisher: Dow Jones Publishing Co. (Europe)
Publication Name: Wall Street Journal. Europe
Subject: Business, international
ISSN: 0921-9986
Year: 2004
France, Company acquisition/merger, Acquisitions and mergers, Aventis S.A., AVE, Hostile takeovers, Sanofi-Sythelabo

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Subjects list: United States, Pharmaceutical industry, Mergers, acquisitions and divestments, Drugs, Switzerland, Novartis AG, NVTSY
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.